In this online CME self-learning program:
Schizophrenia, by nature, presents manifold challenges to the healthcare professional directing neuropsychiatric care. Not only do practical matters like medication adherence play a role in the success of therapy, but it behooves clinicians to also have a well-informed understanding of the symptomatology and treatment course of the disease. Atypical antipsychotics are the mainstay of initial pharmacotherapy, with oral agents being preferred first. However, recent literature has questioned whether earlier treatment with long-acting injectable antipsychotics might improve adherence or whether other treatment modalities like behavioral intervention strategies should be stressed. Poor patient adherence to schizophrenia medications is associated with suboptimal clinical outcomes, and improving adherence may enhance quality of life and reduce the risk of hospitalization, thereby potentially lowering health resource utilization and its associated costs. Adherence is an area that continues to represent a practice gap.
- Faculty member introduction, disclosures
- Major findings from APA 2017, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
Healthcare professionals specializing in: family medicine, internal medicine, mental health, pediatric neurology and psychiatry, or those who otherwise commonly care for pediatric patients with Schizophrenia or related psychiatric diseases.
This program is supported by an educational grant from Alkermes.
Release Date: July 27, 2017 -- Expiration Date: July 27, 2019
Faculty: Rimal Bera, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Rimal Bera, M.D. is on the speaker's bureau of Alkermes, Merck, and Otsuka and has received research funding from AZ, Novartis, and Otsuka.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Alkermes
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.